ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Catalyst Pharmaceuticals, Inc. ?
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 25.28%
- Healthy long term growth as Net Sales has grown by an annual rate of 37.68% and Operating profit at 44.23%
- The company is Net-Debt Free
2
Positive results in Mar 26
- RAW MATERIAL COST(Y) Fallen by -3.88% (YoY)
- CASH AND EQV(HY) Highest at USD 1,465.03 MM
- OPERATING PROFIT(Q) Highest at USD 83.08 MM
3
With ROE of 22.38%, it has a attractive valuation with a 2.99 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 37.57%, its profits have risen by 33.4% ; the PEG ratio of the company is 0.5
4
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 7.09% over the previous quarter.
5
Market Beating performance in long term as well as near term
- Along with generating 37.57% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Catalyst Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Catalyst Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Catalyst Pharmaceuticals, Inc.
37.57%
3.02
33.33%
S&P 500
25.41%
1.92
13.25%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
37.68%
EBIT Growth (5y)
44.23%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.73
Sales to Capital Employed (avg)
0.74
Tax Ratio
23.64%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
116.28%
ROE (avg)
25.28%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
2.99
EV to EBIT
8.34
EV to EBITDA
7.26
EV to Capital Employed
8.75
EV to Sales
3.65
PEG Ratio
0.45
Dividend Yield
NA
ROCE (Latest)
104.99%
ROE (Latest)
22.38%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend8What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -3.88% (YoY
CASH AND EQV(HY)
Highest at USD 1,465.03 MM
OPERATING PROFIT(Q)
Highest at USD 83.08 MM
OPERATING PROFIT MARGIN(Q)
Highest at 55.61 %
PRE-TAX PROFIT(Q)
Highest at USD 79.48 MM
NET PROFIT(Q)
Highest at USD 60.14 MM
EPS(Q)
Highest at USD 0.5
-4What is not working for the Company
DEBTORS TURNOVER RATIO(HY)
Lowest at 5.87 times
INVENTORY TURNOVER RATIO(HY)
Lowest at 4.45 times
Here's what is working for Catalyst Pharmaceuticals, Inc.
Operating Profit
Highest at USD 83.08 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at 55.61 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD 79.48 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 60.14 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 0.5
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Cash and Eqv
Highest at USD 1,465.03 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Raw Material Cost
Fallen by -3.88% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 9.85 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for Catalyst Pharmaceuticals, Inc.
Debtors Turnover Ratio
Lowest at 5.87 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Inventory Turnover Ratio
Lowest at 4.45 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
